Drugs / ATLCAR.CD30
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03602157 | Oct 2018 → Dec 2025 overdue | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Sezary syndrome, immunoproliferative disorder, lymphomatoid papulosis +3 | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05634785 | Dec 2022 → Dec 2025 | nongerminomatous germ cell tumor | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04083495 | Sep 2019 → Feb 2028 expected | peripheral T-cell lymphoma, not otherwise specified | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03914885 | — | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATLCAR.CD30 | “This study will combine both T cells and antibodies in order to create a more effective treatment called Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted...” NCT03602157 ↗ |
| Action | Deplete | “Researchers are working to identify ways to improve the ability of ATLCAR.CD30 to destroy tumor cells.” NCT03602157 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT03602157 ↗ |
| Route | Intravenous | “The cells will be administered by a licensed provider (oncology nurse or physician) via intravenous injection over 1-10 minutes through either a peripheral or a central line.” NCT03602157 ↗ |